Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Tidewater Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.34 (market cap $12.58B), while Tidewater Inc trades at $84.93 (market cap $4.21B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 3× Tidewater Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Tidewater Inc for 26 Days on average.
| HALO | TDW | |
|---|---|---|
Market Cap | $12.58B | $4.21B |
Volume | 2,179,278 | 590,005 |
Sector | Health | Energy |
52-Week High | $115.22 | $100.61 |
52-Week Low | $61.63 | $47.29 |
Typical Hold Time | 1 Days | 26 Days |
Enterprise Value | $14.49B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tidewater (TDW) trades at $85.19, up 2.15% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 earnings have missed expectations in two quarters. Recent news includes the completion of the Wilson Sons Ultratug acquisition in August 2026, and institutional interest remains strong with BlackRock's $503.2M investment.
Outlook is cautiously optimistic with a consensus price target of $105.50, but risks include earnings volatility and competitive pressures. The stock offers potential upside from operational improvements and acquisition synergies, yet investors should monitor execution on future earnings and market conditions in the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
